论文部分内容阅读
全球生命科学和材料科学专业公司荷兰皇家帝斯曼集团近期公布,2013年第二季度EBITDA达到3.45亿欧元,相比2012年第二季度的2.90亿欧元和2013年第一季度的3.11亿欧元均有提升。虽然己内酰胺销售价格下降产生2000万欧元的负面影响,充满挑战的全球宏观经济环境对材料科学领域造成了不利影响,帝斯曼仍然取得了同比盈利水平的提高。对于上述业绩,帝斯曼全球首席执行官兼董事会主席谢白曼表示:“从第一季度末到第二季度,我们的营养业务持续增长,营养业务利润
The Royal DSM Group, a global specialist in life sciences and materials science, recently announced EBITDA of 345 million euros in the second quarter of 2013, compared with 290 million euros in the second quarter of 2012 and 311 million euros in the first quarter of 2013 There are enhancements. Despite the negative impact of a drop of caprolactam sales of 20 million euros, the challenging global macroeconomic environment has adversely affected the material sciences and DSM still achieved year-on-year improvement in profitability. For the above performance, Xie Bieman, chief executive officer and chairman of the board of directors of DSM, said: ”From the end of the first quarter to the second quarter, our nutrition business continued to grow. Nutrition business profit